Patient characteristics
Parameter . | No. of patients . |
---|---|
Sex | |
Male | 32 |
Female | 29 |
Median age, y (range) | 38 (16-55) |
Diagnostic indication for SCT | |
Acute myelogenous leukemia | 17 |
Acute lymphoblastic leukemia | 10 |
Myelodysplastic syndrome | 1 |
Chronic myeloid leukemia | 8 |
Non-Hodgkin lymphoma | 16 |
Multiple myeloma | 8 |
Severe aplastic anemia | 1 |
Stem cell donor type | |
HLA-matched related donor | 39 |
HLA-matched unrelated donor | 22 |
Conditioning regimen | |
Cy + TBI | 35 |
Cy + TBI + ATG | 23 |
Bu + Cy | 3 |
Stem cell source | |
Bone marrow | 51 |
Mobilized peripheral blood | 10 |
Graft characteristics, median (range) | |
CD34+ hematopoietic stem cells, × 106/kg | 1.6 (0.5-8.8) |
CD3+T lymphocytes, × 105/kg | 2.0 (1.0-7.5) |
EBV serology prior to SCT | |
Recipient positive, SCT donor positive | 55 |
Recipient positive, SCT donor negative | 3 |
Recipient negative, SCT donor positive | 3 |
Recipient negative, SCT donor negative | 0 |
Parameter . | No. of patients . |
---|---|
Sex | |
Male | 32 |
Female | 29 |
Median age, y (range) | 38 (16-55) |
Diagnostic indication for SCT | |
Acute myelogenous leukemia | 17 |
Acute lymphoblastic leukemia | 10 |
Myelodysplastic syndrome | 1 |
Chronic myeloid leukemia | 8 |
Non-Hodgkin lymphoma | 16 |
Multiple myeloma | 8 |
Severe aplastic anemia | 1 |
Stem cell donor type | |
HLA-matched related donor | 39 |
HLA-matched unrelated donor | 22 |
Conditioning regimen | |
Cy + TBI | 35 |
Cy + TBI + ATG | 23 |
Bu + Cy | 3 |
Stem cell source | |
Bone marrow | 51 |
Mobilized peripheral blood | 10 |
Graft characteristics, median (range) | |
CD34+ hematopoietic stem cells, × 106/kg | 1.6 (0.5-8.8) |
CD3+T lymphocytes, × 105/kg | 2.0 (1.0-7.5) |
EBV serology prior to SCT | |
Recipient positive, SCT donor positive | 55 |
Recipient positive, SCT donor negative | 3 |
Recipient negative, SCT donor positive | 3 |
Recipient negative, SCT donor negative | 0 |
SCT indicates stem cell transplantation; HLA, human leukocyte antigen; Cy, cyclophosphamide; TBI, total body irradiation; ATG, antithymocyte globulin; Bu, busulfan; and EBV, Epstein-Barr virus.